Hypertension, Resistant to Conventional Therapy
45
4
5
20
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
8.9%
4 terminated out of 45 trials
83.3%
-3.2% vs benchmark
18%
8 trials in Phase 3/4
20%
4 of 20 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 20 completed trials
Clinical Trials (45)
Antihypertensive Mechanisms of Minocycline in Resistant Hypertension
Baroloop Multicenter Trial (Baroloop MCT)
Physical Activity Program for Reducing Blood Pressure in Sleep Apnea Patients With Resistant Hypertension
High Prevalence of Secondary Arterial Hypertension (HIPRESH) with Prospective Systematic Screening in a Cohort of Consecutive Hypertensive Patients Referring to Regional Specialized Center
A Preventive, Multidisciplinary Primary Care Intervention Organized Around a Therapeutic Garden: Acceptability to Patients Suffering from Cardio-neurovascular Pathology and to Those Involved in the Action.
RADIANCE Continued Access Protocol
UK Registry for Baroreflex Activation Therapy
MANP in African Americans With Hypertension
Moderato System in Patients With Hypertension
Moderato System: A Double-Blind Randomized Trial Ver 1.1
Use of Automated Office Blood Pressure Monitoring
Distal Renal Denervation
Sequential Nephron Blockade vs. Dual Blockade Renin-angiotensin System + Bisoprolol in Resistant Arterial Hypertension
Rapid Renal Sympathetic Denervation for Resistant Hypertension
How to Test Success of a Renal Denervation
Renal Denervation in Hypertension
Chemical Renal Ethanol Sympatholysis Under CT Guidance Use for the Control of Therapy-Resistant Hypertension
Safety and Performance Study of the Moderato System
Renal Artery Stenting in Patients With Documented Resistant Hypertension and Atherosclerotic Renal Artery Stenosis (ANDORRA)
Peripheral Chemoreflex/Arterial Baroreflex Interaction in Patients With Electrical Carotid Sinus Stimulation